drugset / Trial / NCT03097848
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
Unknown
450 enrolled
Southwest Hospital, China
Cancer Hospital of Guangxi Medical University · collabChengdu PLA General Hospital · collabFirst Affiliated Hospital of Chongqing Medical University · collabFirst Affiliated Hospital of Guangxi Medical University · collabHenan Cancer Hospital · collabHunan Cancer Hospital · collabSichuan Cancer Hospital and Research Institute · collabSichuan Provincial People's Hospital · collabThe First People's Hospital of Yunnan · collabThe Second Affiliated Hospital of Chongqing Medical University · collabXiangya Hospital of Central South University · collabXinqiao Hospital of Chongqing · collabYunnan Cancer Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet. There's a theoretical advantage of this combination. Hence in this study the efficacy and safety of pre-administrative Sorafenib and Latter radiofrequency ablation (RFA) in Recurrent HCC will be tested in a multicenter prospective cohort study.
Timeline
- Start
- 2017-05-04
- Primary completion
- 2018-12-30
- Completion
- 2018-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | — | — |